AVN-211, Novel and Highly Selective 5-HT6Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease

Molecular Pharmaceutics

Volumn 13, Issue 3, 2016, Pages 945-963

  Ivachtchenko, Alexandre V ^a,b   Lavrovsky, Yan ^d   Ivanenkov, Yan A ^c,e  

^a Alla Chem LLC   (United States)

^b Avineuro Pharmaceuticals   (United States)

^c MOSCOW INSTITUTE OF PHYSICS AND TECHNOLOGY   (Russian Federation)

^d R Pharm Overseas Inc   (United States)

^e MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

5 HT6R; Alzheimer's disease; antagonists; pharmacokinetics; preclinical study; selectivity

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; 5,7 DIMETHYL 2 (METHYLTHIO) 3 (PEHNYLSULFONYL)PYRAZOLO[1,5 A]PYRIMIDINE; APOMORPHINE; BENZODIAZEPINE RECEPTOR; BUSPIRONE; DONEPEZIL; FENOBAM; HALOPERIDOL; IDALOPIRDINE; LORAZEPAM; MEMANTINE; MULTIDRUG RESISTANCE PROTEIN; NOOTROPIC AGENT; PIRACETAM; POTASSIUM CHANNEL HERG; PRX 07034; RUFINAMIDE; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SIBUTRAMINE; TACRINE; UNCLASSIFIED DRUG; 3-SULFONYL-PYRAZOLO(1,5-A)PYRIMIDINE; NEUROPROTECTIVE AGENT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CELL MEMBRANE PERMEABILITY; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STABILITY; DRUG TISSUE LEVEL; ELEVATED PLATFORM TEST; ELEVATED PLUS MAZE TEST; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; ENZYME INHIBITION; EXPLORATORY BEHAVIOR TEST; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; LD50; MALE; MAXIMUM PLASMA CONCENTRATION; MAZE TEST; MEAN RESIDENCE TIME; MEMORY; MEMORY DISORDER; MINIMUM PLASMA CONCENTRATION; MORRIS WATER MAZE TEST; MOUSE; MUTAGEN TESTING; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; OPEN FIELD TEST; PASSIVE AVOIDANCE TEST; PREPULSE INHIBITION; PRIORITY JOURNAL; QT INTERVAL; RADIOASSAY; RAT; RHESUS MONKEY; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING; ALZHEIMER DISEASE; ANIMAL; BAGG ALBINO MOUSE; CACO-2 CELL LINE; CHEMISTRY; DRUG EFFECTS; HIGH THROUGHPUT SCREENING; LIVER; METABOLISM; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; WISTAR RAT;

ALZHEIMER DISEASE; ANIMALS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIVER; MACACA MULATTA; MALE; MICE; MICE, INBRED BALB C; NEUROPROTECTIVE AGENTS; PYRAZOLES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, SEROTONIN; TISSUE DISTRIBUTION;

EID: 84960118284     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00830     Document Type: Article

References (105)

1. World Health Organization, http://www.who.int/en, accessed 16 July, 2015.
2. Zawieja, P.; Kornprobst, J. M.; Métais, P. 3-(2,4-dimethoxybenzylidene)-anabaseine: a promising candidate drug for Alzheimer's disease? Geriatr Gerontol Int. 2012, 12 (3) 365-371 10.1111/j.1447-0594.2011.00827.x
3. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M. B. H. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment Curr. Drug Targets 2012, 13 (4) 483-494 10.2174/138945012799499794
4. A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD). NCT02423122, https://clinicaltrials.gov/ct2/show/NCT02423122, accessed 16 July 2015.
5. Fukunaga, K.; Yabuki, Y. Alzheimer therapeutics ST101 improves the cognition in schizophrenia model rats. 11th World Congr. Biol. Psychiatry 2013, Abstract 024.
6. Khanferyan, R.; Chekanova, O.; Dorofeeva, J.; Galenko-Jaroshevsky, A. Antihistamine drug, Dimebon, with multiple mechanisms of actions Inflamm. Res. 2011, 60, S336
7. Schneider, L. S. Idalopirdine for Alzheimer's disease: written in the stars Lancet Neurol. 2014, 13 (11) 1063-1065 10.1016/S1474-4422(14)70232-7
8. 6receptor antagonism approach in Alzheimer's disease Drugs Future 2014, 39 (2) 133 10.1358/dof.2014.039.02.2103730
9. 6receptor antagonist, SB-742457, in Alzheimer's disease Curr. Alzheimer Res. 2010, 7 (5) 374-385 10.2174/156720510791383831
10. Moebius, H.; Loewen, G.; Dgetluck, N.; Hilt, D. A randomized, double-blind, placebo-controlled, 24-week, phase 2b outcomes study of 3 different doses of encenicline or placebo in subjects with mild to moderate probable Alzheimer's disease. 67th Annu. Meet. Am. Acad. Neurol. (AAN) 2015, Abst P7.100.
11. AC-1204 26-week long term efficacy Response trial with optional open-label ext (NOURISH AD). NCT01741194, https://clinicaltrials.gov/ct2/show/NCT01741194, accessed 16 July 2015.
12. Scott, J. D.; Li, S. W.; Cartwright, M. Discovery of MK-8931: A BACE inhibitor in phase 3 clinical development for Alzheimer's disease. 249th National Meeting of the American Chemical Society; 2015, Abstract MEDI 246.
13. Alexander, R.; Haeberlein, S. B.; Rosen, L. AZD3293 a novel BACE1 inhibitor: Pharmacokinetics and effects on plasma and CSF A-beta peptides following multiple-dose administration in Alzheimer's disease patients. 12th Int. Conf. Alzheimer Parkinson Dis. (AD/PD); 2015, Abstact 091.
14. Baddeley, T. C.; McCaffrey, J.; Storey, J. M. D.; Cheung, J. K. S.; Melis, V.; Horsley, D.; Harrington, C. R.; Wischik, C. M. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease J. Pharmacol. Exp. Ther. 2015, 352 (1) 110-118 10.1124/jpet.114.219352
15. 2+channels Bull. Exp. Biol. Med. 2001, 132, 1079-1083 10.1023/A:1017972709652
16. Bachurin, S. O.; Shevtsova, E. P.; Kireeva, E. G.; Oxenkrug, G. F.; Sablin, S. O. Mitochondria as a target for neurotoxins and neuroprotective agents Ann. N. Y. Acad. Sci. 2003, 993, 334-344 10.1111/j.1749-6632.2003.tb07541.x
17. Grigor'ev, V. V.; Dranyi, O. A.; Bachurin, S. O. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons Bull. Exp. Biol. Med. 2003, 136, 474-477 10.1023/B:BEBM.0000017097.75818.14
18. Cano-Cuenca, N.; Solís-García del Pozo, J. E.; Jordán, J. Evidence for the Efficacy of Latrepirdine (Dimebon) Treatment for Improvement of Cognitive Function: A Meta-Analysis J. Alzheimer's Dis. 2013, 38, 155-164
19. Doody, R. S.; Gavrilova, S. I.; Sano, M.; Thomas, R. G.; Aisen, P. S.; Bachurin, S. O.; Seely, L.; Hung, D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study Lancet 2008, 372, 207-215 10.1016/S0140-6736(08)61074-0
20. Negative Phase III trial results for Dimebon; Alzheimer's Association: http://www.alz.org/norcal/in-my-community-19452.asp, accessed 16 July 2015.
21. Dimebon disappoints in Phase III trial of Huntington's Disease; Medscape: http://www.medscape.com/viewarticle/740692, accessed 16 July 2015.
22. Dar, T. A.; Sheikh, I. A.; Ganie, S. A.; Ali, R.; Singh, L. R.; Gan, S. H.; Kamal, M. A.; Zargar, M. A. Molecular linkages between diabetes and Alzheimer's disease: current scenario and future prospects CNS Neurol. Disord.: Drug Targets 2014, 13 (2) 290-298 10.2174/18715273113126660135
23. Talbot, K.; Wang, H. Y. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease Alzheimer's Dementia 2014, 10 (1Suppl) S12-25 10.1016/j.jalz.2013.12.007
24. Wang, Y.; Serricchio, M.; Jauregui, M.; Shanbhag, R.; Stoltz, T.; Di Paolo, C. T.; Kim, P. K.; McQuibban, G. A. Deubiquitinating enzymes regulate PARK2-mediated mitophagy Autophagy 2015, 11 (4) 595-606 10.1080/15548627.2015.1034408
25. Perluigi, M.; Di Domenico, F.; Butterfield, D. A. mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy Neurobiol. Dis. 2015, 84, 39 10.1016/j.nbd.2015.03.014
26. Landreth, G. E.; Reed-Geaghan, E. G. Toll-like receptors in Alzheimer's disease Curr. Top. Microbiol. Immunol. 2009, 336, 137-153 10.1007/978-3-642-00549-7-8
27. Cho, S. J.; Yun, S. M.; Jo, C.; Lee, D. H.; Choi, K. J.; Song, J. C.; Park, S. I.; Kim, Y. J.; Koh, Y. H. SUMO1 promotes Aβ production via the modulation of autophagy Autophagy 2015, 11 (1) 100-112 10.4161/15548627.2014.984283
28. Skaper, S. D. Wnt-signalling: A new direction for Alzheimer disease? CNS Neurol. Disord.: Drug Targets 2014, 13 (4) 556 10.2174/187152731304140702104826
29. Shibuya, Y.; Niu, Z.; Bryleva, E. Y.; Harris, B. T.; Murphy, S. R.; Kheirollah, A.; Bowen, Z. D.; Chang, C. C.; Chang, T. Y. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage Neurobiol. Aging 2015, 36 (7) 2248-2259 10.1016/j.neurobiolaging.2015.04.002
30. Tanzi, R. E. TREM2 and Risk of Alzheimer's Disease-Friend or Foe? N. Engl. J. Med. 2015, 372 (26) 2564-2565 10.1056/NEJMcibr1503954
31. Yan, R.; Vassar, R. Targeting the β secretase BACE1 for Alzheimer's disease therapy Lancet Neurol. 2014, 13 (3) 319-329 10.1016/S1474-4422(13)70276-X
32. Hall, A.; Patel, T. R. γ-Secretase modulators: current status and future directions Prog. Med. Chem. 2014, 53, 101-145 10.1016/B978-0-444-63380-4.00003-2
33. 6Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia Curr. Pharm. Des. 2015, 21 (26) 3739-3759 10.2174/1381612821666150605112105
34. 6receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease J. Med. Chem. 2014, 57 (17) 7160-7181 10.1021/jm5003952
35. 6receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia EMBO Mol. Med. 2012, 4 (10) 1043-1056 10.1002/emmm.201201410
36. Marin, P.; Meffre, J.; Bockaert, J. The mTOR pathway: a new target for treating cognitive deficits of schizophrenia? Med. Sci. (Paris) 2013, 29 (1) 28-30 10.1051/medsci/2013291009
37. 6receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease Expert Rev. Neurother. 2009, 9 (7) 1073-1085 10.1586/ern.09.51
38. Ramirez, M. J.; Lai, M. K.; Tordera, R. M.; Francis, P. T. Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status Drugs 2014, 74 (7) 729-736 10.1007/s40265-014-0217-5
39. 6receptor antagonists for the treatment of Alzheimer's disease Curr. Top. Med. Chem. 2008, 8 (12) 1035-1048 10.2174/156802608785161420
40. 6receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease Neurotherapeutics 2008, 5 (3) 458-469 10.1016/j.nurt.2008.05.008
41. 6receptors: a novel target for cognitive enhancement Pharmacol. Ther. 2005, 108 (3) 320-333 10.1016/j.pharmthera.2005.05.001
42. Study evaluating the safety and efficacy of PF-05212377 or placebo in subjects with Alzheimer's disease with existing neuropsychiatric symptoms on donepezil. Nct01712074; https://clinicaltrials.gov/ct2/show/NCT01712074, accessed 16 July 2015.
43. 6 receptor antagonist SUVN-502. 12th Int. Conf. Alzheimer's Dis. Relat. Disord. (ICAD) 2009, Abstract P2-264.
44. Lavrovsky, Y.; Ivachtchenko, A. V.; Morozova, M.; Salimov, R. M.; Kasey, V. Preclinical and early clinical studies of AVN-101, a novel balanced molecule for the treatment of Alzheimer's disease Alzheimer's Dementia 2010, 6 (4) S583 10.1016/j.jalz.2010.05.1984
45. Okun, I.; Tkachenko, S. E.; Khvat, A.; Mitkin, O.; Kazey, V.; Ivachtchenko, A. V. From anti-allergic to anti-Alzheimer's: molecular pharmacology of Dimebon Curr. Alzheimer Res. 2010, 7, 97-112 10.2174/156720510790691100
46. Cyprotex S9 stability assay; http://www.cyprotex.com/admepk/in-vitro-metabolism/s9-stability, accessed 16 July 2015.
47. Merck Millipore. http://www.millipore.com, accessed 16 July 2015.
48. Vivid® CYP450 screening kits protocol; https://tools.lifetechnologies.com/downloads/O-13873-r1-US-0405.pdf, accessed 16 July 2015.
49. Guide for the Care and Use of Laboratory Animals; National Academy Press: Washington, DC, 1996.
50. 6 receptors, methods for the production and the use thereof. Patent RU2369600, 2009.
51. Ivachtchenko, A. V.; Golovina, E. S.; Kadieva, M. G.; Koryakova, A. G.; Mitkin, O. D.; Tkachenko, S. E.; Kysil, V. M.; Okun, I. 2-Substituted 5,6-dimethyl-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines: New series of highly potent and specific serotonin 5-HT6 receptor antagonists Eur. J. Med. Chem. 2011, 46, 1189-1197 10.1016/j.ejmech.2011.01.038
52. 6 receptors. In Chemistry and medicine for the 70th anniversary of academician Yunusov M. S., Abstr. VIII All-Russ. Sci. Conf. with Intern. Participation 2010, Inst. Organic Chem. Ufa Sci. Centre RAS: Russia, Ufa.
53. 6R Ligands: A Comprehensive Insight into their Selectivity and Activity Curr. Bioact. Compd. 2013, 9, 64-100 10.2174/1573407211309010007
54. 6antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats Int. J. Neuropsychopharmacol. 2010, 13, 1021-1033 10.1017/S1461145710000659
55. 6receptor antagonist SB-742457 as a novel cognitive enhancing agent for Alzheimer's disease Alzheimer's Dementia 2006, 2 (3) S631-S632 10.1016/j.jalz.2006.05.2128
56. th anniversary of the birth of Professor N. Prostakov, Peoples' Friendship University of Russia (RUDN) 2012, Moscow, Russia, abstracts.
57. Hutcheson, J. D.; Setola, V.; Roth, B. L.; Merryman, W. D. Serotonin receptors and heart valve disease-it was meant 2B Pharmacol. Ther. 2011, 132 (2) 146-157 10.1016/j.pharmthera.2011.03.008
58. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.; Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. S. Rational use of in vitro P-glycoprotein assays in drug discovery J. Pharmacol. Exp. Ther. 2001, 299, 620-628
59. Bromidge, S. M.; Brown, A. M.; Clarke, S. E.; Dodgson, K.; Gager, T.; Grassam, H. L.; Jeffrey, P. M.; Joiner, G. F.; King, F. D.; Middlemiss, D. N.; Moss, S. F.; Newman, H.; Riley, G.; Routledge, C.; Wyman, P. 5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist J. Med. Chem. 1999, 42, 202-205 10.1021/jm980532e
60. 6receptor antagonists J. Med. Chem. 2012, 55, 9255-9269 10.1021/jm300955x
61. 6antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134) Bioorg. Med. Chem. Lett. 2001, 11, 55-58 10.1016/S0960-894X(00)00597-7
62. 6receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist J. Med. Chem. 2003, 46, 1273-1276 10.1021/jm021085c
63. 6receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats Neurobiol. Learn. Mem. 2011, 96, 392-402 10.1016/j.nlm.2011.06.015
64. 6receptor antagonists Bioorg. Med. Chem. Lett. 2005, 15, 4867-4871 10.1016/j.bmcl.2005.06.107
65. 6receptor ligands Bioorg. Med. Chem. Lett. 2012, 22, 7431-7435 10.1016/j.bmcl.2012.10.057
66. 6antagonists Bioorg. Med. Chem. Lett. 2012, 22, 1494-1498 10.1016/j.bmcl.2012.01.022
67. 6receptor antagonist showing activity in rat social recognition test Bioorg. Med. Chem. Lett. 2012, 22, 1421-1426 10.1016/j.bmcl.2011.12.026
68. 6antagonists Bioorg. Med. Chem. Lett. 2009, 19, 2409-2412 10.1016/j.bmcl.2009.03.077
69. 6antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats Int. J. Neuropsychopharmacol. 2010, 13, 1021-1033 10.1017/S1461145710000659
70. Sang, Z.; Qiang, X.; Li, Y.; Yuan, W.; Liu, Q.; Shi, Y.; Ang, W.; Luo, Y.; Tan, Z.; Deng, Y. Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer's disease Eur. J. Med. Chem. 2015, 94, 348-366 10.1016/j.ejmech.2015.02.063
71. Liu, M. Y.; Wang, S.; Yao, W. F.; Zhang, Z. J.; Zhong, X.; Sha, L.; He, M.; Zheng, Z. H.; Wei, M. J. Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice Neuroscience 2014, 273, 141-151 10.1016/j.neuroscience.2014.05.011
72. Spiazzi, C. C.; Soares, M. B.; Izaguirry, A. P.; Vargas, L. M.; Zanchi, M. M.; Pavin, N. F.; Affeldt, R. F.; Lüdtke, D. S.; Prigol, M.; Santos, F. W. Selenofuranoside ameliorates memory loss in Alzheimer-like sporadic dementia: AChE activity, oxidative stress, and inflammation involvement Oxid. Med. Cell. Longevity 2015, 2015, 976908 10.1155/2015/976908
73. Chao, F.; Zhang, L.; Luo, Y.; Xiao, Q.; Lv, F.; He, Q.; Zhou, C.; Zhang, Y.; Jiang, L.; Jiang, R.; Gu, H.; Tang, Y. Running Exercise Reduces Myelinated Fiber Loss in the Dentate Gyrus of the Hippocampus in APP/PS1 Transgenic Mice Curr. Alzheimer Res. 2015, 12 (4) 377-383 10.2174/1567205012666150325183011
74. Bryson, H. M.; Benfield, P. Donepezil Drugs Aging 1997, 10 (3) 234-239 10.2165/00002512-199710030-00007
75. 6receptors in nigro-striatal function in rodents Br. J. Pharmacol. 1998, 125, 1562-1566 10.1038/sj.bjp.0702230
76. Bristow, L. J.; Collinson, N.; Cook, G. P.; Curtis, N.; Freedman, S. B.; Kulagowski, J. J.; Leeson, P. D.; Patel, S.; Ragan, C. I.; Ridgill, M.; Saywell, K. L.; Tricklebank, M. D. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests J. Pharmacol. Exp. Ther. 1997, 283 (3) 1256-1263
77. Lesem, M. A randomized, placebo-controlled phase IIa trial of SGS518 for treating cognitive impairment associated with schizophrenia. 11th Int. Congr. Schizophr. Res. 2007, Abstract.
78. Efficacy study exploring the effect of Lu AE58054 as augmentation therapy in patients with schizophrenia. NCT00810667; https://clinicaltrials.gov/ct2/show/NCT00810667, accessed 16 July 2015.
79. Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil (STARBEAM). NCT02006641; https://clinicaltrials.gov/ct2/show/NCT02006641, accessed 16 July 2015.
80. Study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil (STARSHINE). NCT01955161; https://clinicaltrials.gov/ct2/show/NCT01955161, accessed 16 July 2015.
81. Lu AE58054 in patients with mild to moderate Alzheimer's disease treated with an acetylcholinesterase inhibitor (STARBRIGHT). NCT02006654; https://clinicaltrials.gov/ct2/show/NCT02006654, accessed 16 July 2015.
82. Long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease (STAR Extension). NCT02079246; https://clinicaltrials.gov/ct2/show/NCT02079246, accessed 16 July 2015.
83. Lu AE58054 added to donepezil for the treatment for moderate Alzheimer's disease. NCT01019421; https://clinicaltrials.gov/ct2/show/NCT01019421, accessed 16 July 2015.
84. 6receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial Lancet Neurol. 2014, 13 (11) 1092-1099 10.1016/S1474-4422(14)70198-X
85. 6 ligands. Patent WO2003080580, 2004.
86. Johnson, C. N.; Witty, D. Quinoline compounds and pharmaceutical compositions containing them. Patent WO2005026125, 2005.
87. Gladwin, A. E. A polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline. Patent WO 2005040124, 2005.
88. Chuang, T. T.; Hunter, A. J.; Virley, D. J. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline. Patent WO2009074607, 2009.
89. Arnt, J.; Bang-Andersen, B.; Dias, R.; Bøgesø, K. P. Strategies for pharmacotherapy of schizophrenia Drugs Future 2008, 33 (9) 777-791 10.1358/dof.2008.033.09.1236966
90. Maher-Edwards, G.; Dixon, R.; Hunter, J.; Gold, M.; Hopton, G.; Jacobs, G.; Hunter, J.; Williams, P. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study Int. J. Geriatr Psychiatry 2011, 26 (5) 536-544 10.1002/gps.2562
91. 6receptor antagonist, SB-742457, in Alzheimer's disease Curr. Alzheimer Res. 2010, 7 (5) 374-385 10.2174/156720510791383831
92. 6receptor antagonist, SB-742457, in Alzheimer's disease Curr. Alzheimer Res. 2010, 7 (5) 374-385 10.2174/156720510791383831
93. Axovant RVT-101, http://www.axovant.com/rvt-101/, accessed 16 July 2015; ClinicalTrials.gov Identifier: NCT02585934.
94. 6receptors AVN211 (CD0080173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study CNS Spectr. 2014, 19 (4) 316-323 10.1017/S1092852913000394
95. 6 receptor antagonist; http://www.biospace.com/News/avineuro-completed-phase-ii-clinical-study-of-avn/384442/source=MoreNews, accessed 16 July 2015.
96. Gravius, A.; Laszy, J.; Pietraszek, M.; Sághy, K.; Nagel, J.; Chambon, C.; Wegener, N.; Valastro, B.; Danysz, W.; Gyertyán, I. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity Behav. Pharmacol. 2011, 22 (2) 122-135 10.1097/FBP.0b013e328343d804
97. 6receptor ligands and their biological functions Curr. Top. Med. Chem. 2002, 2 (6) 643-654 10.2174/1568026023393877
98. 6) receptor antagonists in rodent models of learning J. Pharmacol. Exp. Ther. 2003, 307 (2) 682-691 10.1124/jpet.103.056002
99. 6receptor antagonist, Ro4368554, in rat models for cognition and sensorimotor gating Eur. Neuropsychopharmacol. 2007, 17, 277-288 10.1016/j.euroneuro.2006.06.009
100. 6receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat Br. J. Pharmacol. 2008, 155, 434-440 10.1038/bjp.2008.281
101. 6receptor antagonist, SB-271046, in animal models for schizophrenia Pharmacol., Biochem. Behav. 2002, 71, 635-643 10.1016/S0091-3057(01)00743-2
102. 6receptor antagonist, Ro4368554, restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat Neuropsychopharmacology 2005, 30, 2169-2179 10.1038/sj.npp.1300777
103. 6receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats Neuropsychopharmacology 2004, 29, 93-100 10.1038/sj.npp.1300332
104. 6receptor antagonist, Ro4368554, in rat models for cognition and sensorimotor gating Eur. Neuropsychopharmacol. 2007, 17, 277-288 10.1016/j.euroneuro.2006.06.009
105. 6receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat Br. J. Pharmacol. 2008, 155, 434-440 10.1038/bjp.2008.281